Status and phase
Conditions
Treatments
About
The folate receptor is overexpressed in many types of cancer, including ovarian and endometrial cancer, and the level of folate receptor expression increases with the stage of the disease. Technetium Tc 99m EC20 (99mTc-EC20; FolateScan), a folate-targeted diagnostic radiopharmaceutical, is designed to bind to the folate receptor. Thus, FolateScan may provide an effective method to determine folate receptor-positive (FR+) target tumors, thereby assisting in the identification of those patients who may benefit from folate-targeted therapy.
Full description
This phase 2, two-center, open-label, single-treatment group, within-patient-controlled study was conducted to:
Expand the safety database and gather data on the percentage of patients with known or suspected ovarian carcinoma or recurrent endometrial carcinoma who show increased uptake of FolateScan in tumors (primary objective). Calculate the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of FolateScan compared with immunohistochemical (IHC) staining (secondary objective).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects must meet the following eligibility requirements to be enrolled in the study.
Exclusion criteria
Subjects must be excluded if any of the following conditions are present:
Primary purpose
Allocation
Interventional model
Masking
16 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal